FREAMINE 8.5%
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FREAMINE 8.5% (FREAMINE 8.5%).
FREAMINE 8.5% is a crystalline amino acid solution that provides essential and nonessential amino acids for protein synthesis, maintenance of nitrogen balance, and tissue repair in patients unable to tolerate oral or enteral nutrition.
| Metabolism | Amino acids are metabolized primarily in the liver via deamination, transamination, and urea cycle pathways. |
| Excretion | Amino acids from FREAMINE 8.5% are primarily metabolized via deamination and transamination pathways, with nitrogen waste excreted renally as urea (approx 80-90% of administered nitrogen). A small fraction is excreted via feces as unabsorbed amino acids (less than 5%). Biliary excretion is negligible. |
| Half-life | The terminal elimination half-life of infused amino acids is not conventionally defined as it depends on metabolic utilization. For most amino acids, plasma clearance is rapid (minutes to hours) with a pseudo-half-life of approximately 15-30 minutes for the initial distribution phase. Clinical context: half-life is irrelevant since amino acids are continuously metabolized and incorporated into proteins. |
| Protein binding | Amino acids are not significantly protein-bound. Most circulate in free form (less than 5% binding to albumin or other proteins). |
| Volume of Distribution | Volume of distribution for total amino acids is approximately 0.2-0.3 L/kg, corresponding to extracellular fluid space. This reflects rapid equilibration with interstitial fluid. |
| Bioavailability | Intravenous: 100%. Oral: Not applicable as FREAMINE 8.5% is not administered orally; if ingested, bioavailability is near 100% due to complete absorption, but the product is for IV use only. |
| Onset of Action | Intravenous: Immediate upon infusion. Clinical effects (improvement in nitrogen balance) occur within hours of administration, reflecting rapid uptake into cells and stimulation of protein synthesis. |
| Duration of Action | Duration depends on infusion rate and total dose. Provision of adequate caloric intake extends the anabolic effect. Discontinuation of infusion leads to a decline in plasma amino acid levels within minutes to hours, with nitrogen balance returning to pre-infusion status within 24 hours if no other nutrition is provided. |
1 to 2 g/kg/day intravenously, typical adult dose 70-140 g/day (800-1650 mL of 8.5% solution), infused at a rate not exceeding 0.1 g/kg/hour
| Dosage form | INJECTABLE |
| Renal impairment | For GFR < 25 mL/min: restrict to 0.5-0.8 g/kg/day and monitor serum BUN and electrolytes; GFR 25-50 mL/min: 0.8-1.0 g/kg/day; GFR > 50 mL/min: usual dose |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and monitor ammonia; Child-Pugh C: avoid use or use with extreme caution at 0.5-0.7 g/kg/day |
| Pediatric use | Infants and children: 2-3 g/kg/day intravenously; neonates: start at 0.5-1 g/kg/day, increase gradually to 2-3 g/kg/day; monitor fluid and electrolyte balance |
| Geriatric use | No specific dose adjustment, but start at lower end of dosing range (0.8-1 g/kg/day) due to potential renal impairment and decreased protein requirements |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for FREAMINE 8.5% (FREAMINE 8.5%).
| Breastfeeding | FREAMINE 8.5% is a standard component of parenteral nutrition. Amino acids are normally present in breast milk. Supplemental amino acids enter maternal circulation and may increase milk protein content. M/P ratio not established. Generally considered compatible with breastfeeding under medical supervision. |
| Teratogenic Risk | No known teratogenic effects in animal studies. Amino acid solutions are essential nutrients; when used as indicated, risks are not established but may be beneficial in maternal malnutrition. Trimester-independent; no specific fetal risks reported with proper use. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Hepatic coma or severe hepatic insufficiency","Inborn errors of amino acid metabolism","Severe azotemia or hyperammonemia","Hypersensitivity to any component"]
| Precautions | ["Risk of hyperglycemia, hyperosmolality, and osmotic diuresis due to dextrose content (if present in formulation)","Electrolyte imbalances, particularly hyperkalemia, hyperphosphatemia, and hyperammonemia","Fluid overload in patients with renal or cardiac impairment","Metabolic acidosis in patients with renal failure or hepatic insufficiency","Aluminum toxicity with prolonged use in renal impairment"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal electrolytes, blood glucose, fluid balance, hepatic and renal function, and nitrogen balance. In pregnancy, monitor fetal growth and amniotic fluid volume with serial ultrasounds if long-term therapy is used. |
| Fertility Effects | No known direct effects on fertility. Correction of maternal malnutrition may improve reproductive function. No evidence of impairment in animal studies. |